What is William Blair’s Forecast for Hologic Q1 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for Hologic in a research report issued to clients and investors on Monday, November 11th. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will earn $1.00 per share for the quarter, down from their prior forecast of $1.02. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. William Blair also issued estimates for Hologic’s FY2026 earnings at $4.62 EPS.

Several other equities research analysts have also recently commented on HOLX. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, November 6th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Royal Bank of Canada lifted their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. Finally, Leerink Partners decreased their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Stock Up 0.5 %

Shares of NASDAQ HOLX opened at $79.76 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average of $80.88 and a 200 day moving average of $78.22. Hologic has a 12-month low of $67.59 and a 12-month high of $84.67. The stock has a market cap of $18.53 billion, a PE ratio of 23.95, a P/E/G ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the firm posted $0.89 EPS. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis.

Hedge Funds Weigh In On Hologic

Several institutional investors have recently bought and sold shares of HOLX. Innealta Capital LLC acquired a new position in shares of Hologic in the second quarter valued at approximately $25,000. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the third quarter worth $25,000. iA Global Asset Management Inc. purchased a new stake in Hologic during the 1st quarter worth about $37,000. Sunbelt Securities Inc. acquired a new position in shares of Hologic during the 2nd quarter worth about $37,000. Finally, First Horizon Advisors Inc. raised its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.